NeXT Personal Gains Key Medicare Coverage for Breast Cancer Pre-Surgical Monitoring
PSNL sits 91% above its 52-week low of $3.84.
Summary
Personalis has secured its fourth Medicare coverage decision for its NeXT Personal test, specifically expanding coverage to include pre-surgical treatment monitoring for breast cancer, including neoadjuvant therapy for Stage II-III TNBC or HER2+ breast cancer. This is a significant positive development, as expanded Medicare coverage directly increases the addressable market and potential revenue for the company's key diagnostic product. This news provides a much-needed catalyst following the company's recent Q1 2026 report, which showed a 25% year-over-year revenue decline and a doubled net loss, despite strong clinical test volume growth. Investors will now watch for the commercial impact of this expanded coverage on future financial results.
At the time of this announcement, PSNL was trading at $7.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $737.2M. The 52-week trading range was $3.84 to $11.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.